Nelfinavir

Evidence Level: L5

Predicted Indications: 4

Nelfinavir

Pharmacist Assessment Report

Nelfinavir: From HIV Infection to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Nelfinavir is an HIV-1 protease inhibitor originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for simian immunodeficiency virus (SIV) infection, but there are no registered clinical trials and only 3 publications (all in vitro or indirect), so the evidence is preclinical at best.

Quick Overview

Item	Content
Original Indication	HIV infectious disease, AIDS
Predicted New Indication	Simian immunodeficiency virus infection
TxGNN Prediction Score	0.9994
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Nelfinavir is an HIV-1 protease inhibitor. Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, nelfinavir belongs to the protease inhibitor class and its efficacy in HIV infection is established.

SIV is a closely related lentivirus with a homologous protease, so a protease-inhibition rationale is plausible. The retrieved literature consists of in vitro susceptibility work on HIV-2, SIV and SHIV against anti-HIV-1 compounds. This is indirect, preclinical evidence only.

The high score mostly reflects similarity to the original HIV indication rather than a new therapeutic opportunity. SIV infection is a non-human primate model, not a human clinical indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15040537	2004	In vitro susceptibility study	Antiviral Therapy	Tested 16 approved anti-HIV drugs and one experimental drug against HIV-2, SIV and SHIV strains to guide treatment and post-exposure prophylaxis
12234864	2002	In vitro study	Antimicrob Agents Chemother	Diketo integrase inhibitor L-708,906 inhibited HIV-1, HIV-2 and SIV (mac251) replication; combination with nelfinavir was subsynergistic. Not specific to nelfinavir
12176326	2002	In vitro study	Current Biology	New class of HIV integrase inhibitors blocking viral replication in cell culture. Not specific to nelfinavir

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
156773	Neivex 250mg Tablet	Strip of 10 tablets	Not specified
155565	Nel 250mg Tablet	Strip of 10 tablets	Not specified

Safety Considerations

Contraindications (from the TxGNN model (deep learning), not label text; these may reflect similarities the model learned between related diseases, not biological evidence): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, hyperglycemia, diabetes mellitus, diabetic ketoacidosis, hemophilia, diarrheal disease.
Drug Interactions: 254 interactions were identified in total. Examples from the interactions reviewed:
- Major: rabeprazole, omeprazole, loperamide, triamcinolone, budesonide
- Moderate: acarbose, metformin, alogliptin, albiglutide, canagliflozin, chlorpropamide, hydrocortisone, dexamethasone, betamethasone, alosetron, aprepitant
- Minor: famotidine, ranitidine

Please also refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The only support is indirect in vitro work, with no clinical trials. SIV infection is an animal model rather than a human indication, so the high TxGNN score reflects similarity to HIV rather than a new opportunity. The other predictions are weaker still: feline AIDS is a veterinary indication with no evidence, a rare neurodevelopmental disorder has no clear mechanistic link, and obsolete familial combined hyperlipidemia points toward possible harm, since protease inhibitors are known to cause dyslipidemia.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulator, to enable safety screening
Detailed mechanism of action data (MOA)
Identification of a human-relevant indication, for example by reviewing other predictions or established off-target effects of nelfinavir
Direct nelfinavir susceptibility data in SIV or relevant models, if this direction is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.